(ChemotherapyAdvisor) – Transarterial chemoembolization (TACE) with sequential sorafenib delayed time to progression (TTP) of intermediate-stage hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection, a prospective randomized study concluded in The Oncologist online February 14.
The study enrolled 80 patients with Barcelona Clinic Liver Cancer stage B HCC, Child-Pugh class A disease, and HCV infection. All underwent TACE and were randomized 1:1 to receive sorafenib 400mg twice daily or placebo. Endpoints were TTP and rates of adverse events and toxicity.
Of the 62 patients evaluable, median TTP was 9.2 months in the sorafenib group (n=31) and 4.9 months in the placebo group (n=31) (HR=2.5; P<0.001). “Metachronous, multicentric HCC progression occurred less frequently in sorafenib-treated patients,” the authors noted. Nine patients (22%) in the sorafenib group withdrew from the study due to adverse events.